{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T17:47:43Z","timestamp":1771264063509,"version":"3.50.1"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T00:00:00Z","timestamp":1652313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To evaluate the effectiveness of empirical therapy with \u03b2-lactam\/\u03b2-lactamase inhibitor combinations (BL\/BLICs) for MSSA bacteraemia.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a post hoc analysis of all adult patients with MSSA bacteraemia who were hospitalized at a Spanish university hospital between 2013 and 2018. We compared 30\u2005day mortality among patients receiving initial therapy with BL\/BLICs (de-escalated to cloxacillin or cefazolin within 96\u2005h) versus cloxacillin or cefazolin, using propensity score analysis with the inverse probability of treatment weighting (IPTW) method.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We evaluated 373 patients with MSSA bacteraemia. Among them, 198 patients met the eligibility criteria, including 127 patients in the BL\/BLICs group and 71 patients in the cloxacillin\/cefazolin group. Patients in the BL\/BLICs group had a higher Charlson comorbidity index (median, 2 [IQR, 1\u20134.5] versus 2 [IQR, 0\u20134]); an increased proportion of high-risk sources (i.e. endocarditis, respiratory sources and bacteraemia of unknown origin [34.6% versus 18.3%]); and an earlier start of antibiotic treatment (median, 0\u2005days [IQR, 0\u20130] versus 1\u2005day [IQR, 1\u20132]). Thirty day mortality did not significantly differ between the BL\/BLICs and the cloxacillin\/cefazolin groups (27 patients [21.3%] versus 13 patients [18.3%]; IPTW-adjusted OR\u200a=\u200a0.53 [95% CI, 0.18\u20131.51]). For secondary outcomes, 7\u2005day mortality and 90\u2005day relapse were not statistically different between study groups (8.7% versus 5.6% [P\u200a=\u200a0.62] and 6.2% versus 3.8% [P\u200a=\u200a0.81], respectively).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>BL\/BLICs might be an effective empirical treatment for MSSA bacteraemia when de-escalated to cloxacillin or cefazolin within 96\u2005h from the index blood culture.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkac152","type":"journal-article","created":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T19:27:42Z","timestamp":1651001262000},"page":"2288-2295","source":"Crossref","is-referenced-by-count":12,"title":["Empirical use of \u03b2-lactam\/\u03b2-lactamase inhibitor combinations does not increase mortality compared with cloxacillin and cefazolin in methicillin-susceptible <i>Staphylococcus aureus<\/i> bacteraemia: a propensity-weighted cohort study"],"prefix":"10.1093","volume":"77","author":[{"given":"Rein","family":"Willekens","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Vall d\u2019Hebron Hospital Universitari , Barcelona , Spain"},{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona , Bellaterra , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0722-2218","authenticated-orcid":false,"given":"Mireia","family":"Puig-Asensio","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Hospital Universitari de Bellvitge, L\u2019Hospitalet de Llobregat , Spain"},{"name":"Red Espa\u00f1ola de Investigaci\u00f3n en Patolog\u00eda Infecciosa (REIPI), Instituto de Salud Carlos III , Madrid , Spain"},{"name":"Centro de Investigaci\u00f3n en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6871-0098","authenticated-orcid":false,"given":"Paula","family":"Suanzes","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Vall d\u2019Hebron Hospital Universitari , Barcelona , Spain"},{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona , Bellaterra , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuria","family":"Fern\u00e1ndez-Hidalgo","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Vall d\u2019Hebron Hospital Universitari , Barcelona , Spain"},{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona , Bellaterra , Spain"},{"name":"Red Espa\u00f1ola de Investigaci\u00f3n en Patolog\u00eda Infecciosa (REIPI), Instituto de Salud Carlos III , Madrid , Spain"},{"name":"Centro de Investigaci\u00f3n en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria N","family":"Larrosa","sequence":"additional","affiliation":[{"name":"Red Espa\u00f1ola de Investigaci\u00f3n en Patolog\u00eda Infecciosa (REIPI), Instituto de Salud Carlos III , Madrid , Spain"},{"name":"Centro de Investigaci\u00f3n en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid , Spain"},{"name":"Department of Microbiology, Vall d\u2019Hebron Hospital Universitari , Barcelona , Spain"},{"name":"Department of Genetics and Microbiology, Universitat Aut\u00f2noma de Barcelona , Bellaterra , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan J","family":"Gonz\u00e1lez-L\u00f3pez","sequence":"additional","affiliation":[{"name":"Red Espa\u00f1ola de Investigaci\u00f3n en Patolog\u00eda Infecciosa (REIPI), Instituto de Salud Carlos III , Madrid , Spain"},{"name":"Centro de Investigaci\u00f3n en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid , Spain"},{"name":"Department of Microbiology, Vall d\u2019Hebron Hospital Universitari , Barcelona , Spain"},{"name":"Department of Genetics and Microbiology, Universitat Aut\u00f2noma de Barcelona , Bellaterra , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6781-5405","authenticated-orcid":false,"given":"Dolors","family":"Rodr\u00edguez-Pardo","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Vall d\u2019Hebron Hospital Universitari , Barcelona , Spain"},{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona , Bellaterra , Spain"},{"name":"Red Espa\u00f1ola de Investigaci\u00f3n en Patolog\u00eda Infecciosa (REIPI), Instituto de Salud Carlos III , Madrid , Spain"},{"name":"Centro de Investigaci\u00f3n en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carles","family":"Pigrau","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Vall d\u2019Hebron Hospital Universitari , Barcelona , Spain"},{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona , Bellaterra , Spain"},{"name":"Red Espa\u00f1ola de Investigaci\u00f3n en Patolog\u00eda Infecciosa (REIPI), Instituto de Salud Carlos III , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benito","family":"Almirante","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Vall d\u2019Hebron Hospital Universitari , Barcelona , Spain"},{"name":"Department of Medicine, Universitat Aut\u00f2noma de Barcelona , Bellaterra , Spain"},{"name":"Red Espa\u00f1ola de Investigaci\u00f3n en Patolog\u00eda Infecciosa (REIPI), Instituto de Salud Carlos III , Madrid , Spain"},{"name":"Centro de Investigaci\u00f3n en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,5,12]]},"reference":[{"key":"2022072817542460100_dkac152-B1","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1128\/CMR.00002-14","article-title":"Population-based epidemiology and microbiology of community-onset bloodstream infections","volume":"27","author":"Laupland","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"2022072817542460100_dkac152-B2","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1111\/j.1469-0691.2010.03089.x","article-title":"Epidemiology and clinical features of community-acquired, healthcare-associated and nosocomial bloodstream infections in tertiary-care and community hospitals","volume":"16","author":"Rodr\u00edguez-Ba\u00f1o","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"2022072817542460100_dkac152-B3","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1086\/598189","article-title":"Staphylococcus aureus bacteremia: Epidemiology, pathophysiology, and management strategies","volume":"48","author":"Nabera","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2022072817542460100_dkac152-B4","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1128\/CMR.00134-14","article-title":"Staphylococcus aureus infections: Epidemiology, pathophysiology, clinical manifestations, and management","volume":"28","author":"Tong","year":"2015","journal-title":"Clin Microbiol Rev"},{"key":"2022072817542460100_dkac152-B5","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1093\/cid\/ciz112","article-title":"Changing Characteristics of Staphylococcus aureus Bacteremia: Results from a 21-Year, Prospective, Longitudinal Study","volume":"69","author":"Souli","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2022072817542460100_dkac152-B6","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jinf.2018.08.015","article-title":"Survival following Staphylococcus aureus bloodstream infection: A prospective multinational cohort study assessing the impact of place of care","volume":"77","author":"Nambiar","year":"2018","journal-title":"J Infect"},{"key":"2022072817542460100_dkac152-B7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0170236","article-title":"Characteristics of Staphylococcus aureus bacteraemia and predictors of early and late mortality","volume":"12","author":"Bassetti","year":"2017","journal-title":"PLoS One"},{"key":"2022072817542460100_dkac152-B8","doi-asserted-by":"crossref","first-page":"948.e1","DOI":"10.1016\/j.cmi.2016.07.034","article-title":"Factors associated with 12\u2005week case-fatality in Staphylococcus aureus bacteraemia: a prospective cohort study","volume":"22","author":"Braquet","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"2022072817542460100_dkac152-B9","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jinf.2013.10.015","article-title":"Staphylococcus aureus bloodstream infection: a pooled analysis of five prospective, observational studies","volume":"68","author":"Kaasch","year":"2014","journal-title":"J Infect"},{"key":"2022072817542460100_dkac152-B10","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.jinf.2021.10.001","article-title":"Mortality in Staphylococcus aureus bacteraemia remains high despite adherence to quality indicators: secondary analysis of a prospective cohort study","volume":"83","author":"Willekens","year":"2021","journal-title":"J Infect"},{"key":"2022072817542460100_dkac152-B11","article-title":"Antimicrobial resistance in the EU\/EEA (EARS-Net) \u2013 Annual Epidemiological Report 2019","author":"ECDC","year":"2000"},{"key":"2022072817542460100_dkac152-B12","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.ijantimicag.2016.09.007","article-title":"Multifaceted antibiotic treatment analysis of methicillin-sensitive Staphylococcus aureus bloodstream infections","volume":"48","author":"Weber","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"2022072817542460100_dkac152-B13","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.cmi.2019.03.010","article-title":"Cefazolin vs. anti-staphylococcal penicillins for the treatment of patients with Staphylococcus aureus bacteraemia","volume":"25","author":"Weis","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"2022072817542460100_dkac152-B14","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1186\/s12879-018-3418-9","article-title":"Efficacy and safety of cefazolin vs. antistaphylococcal penicillins for the treatment of methicillin-susceptible Staphylococcus aureus bacteremia: A systematic review and meta-analysis","volume":"18","author":"Shi","year":"2018","journal-title":"BMC Infect Dis"},{"key":"2022072817542460100_dkac152-B15","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s40121-019-00259-4","article-title":"Cefazolin Vs. anti-staphylococcal penicillins for the treatment of patients with methicillin-susceptible Staphylococcus aureus infection: A meta-analysis with trial sequential analysis","volume":"8","author":"Allen","year":"2019","journal-title":"Infect Dis Ther"},{"key":"2022072817542460100_dkac152-B16","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1111\/j.1469-0691.2010.03425.x","article-title":"Are all \u03b2-lactams similarly effective in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia?","volume":"17","author":"Paul","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"2022072817542460100_dkac152-B17","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s00134-018-5085-0","article-title":"The surviving sepsis campaign bundle: 2018 update","volume":"44","author":"Levy","year":"2018","journal-title":"Intensive Care Med"},{"key":"2022072817542460100_dkac152-B18","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/cid\/civ308","article-title":"Comparative effectiveness of \u03b2-lactams vs. vancomycin for treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections among 122 hospitals","volume":"61","author":"McDanel","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2022072817542460100_dkac152-B19","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1086\/502156","article-title":"Role of comorbidity in mortality related to Staphylococcus aureus bacteremia: a prospective study using the Charlson weighted index of comorbidity","volume":"24","author":"Lesens","year":"2003","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2022072817542460100_dkac152-B20","doi-asserted-by":"crossref","first-page":"791","DOI":"10.7326\/0003-4819-137-10-200211190-00007","article-title":"Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections","volume":"137","author":"Friedman","year":"2002","journal-title":"Ann Intern Med"},{"key":"2022072817542460100_dkac152-B21","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"2022072817542460100_dkac152-B22","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/0196-6553(88)90053-3","article-title":"CDC definitions for nosocomial infections, 1988","volume":"16","author":"Garner","year":"1988","journal-title":"Am J Infect Control"},{"key":"2022072817542460100_dkac152-B23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/599376","article-title":"Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the infectious diseases society of America","volume":"49","author":"Mermel","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2022072817542460100_dkac152-B24","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/cid\/ciy916","article-title":"Early oral switch to linezolid for low-risk patients with Staphylococcus aureus bloodstream infections: A propensity-matched cohort study","volume":"69","author":"Willekens","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2022072817542460100_dkac152-B25","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/01621459.1987.10478441","article-title":"Model-Based Direct Adjustment","volume":"82","author":"Rosenbaum","year":"1987","journal-title":"J Am Stat Assoc"},{"key":"2022072817542460100_dkac152-B26","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1128\/CMR.05022-11","article-title":"Predictors of mortality in Staphylococcus aureus bacteremia","volume":"25","author":"van Hal","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"2022072817542460100_dkac152-B27","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"key":"2022072817542460100_dkac152-B28","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1093\/eurheartj\/ehv319","article-title":"2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC) Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM)","volume":"36","author":"Habib","year":"2015","journal-title":"Eur Heart J"},{"key":"2022072817542460100_dkac152-B29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-016-1564-5","article-title":"Comparison of outcomes in patients with methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia who are treated with \u03b2-lactam vs. vancomycin empiric therapy: A retrospective cohort study","volume":"16","author":"Wong","year":"2016","journal-title":"BMC Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/8\/2288\/45180468\/dkac152.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/8\/2288\/45180468\/dkac152.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T17:56:11Z","timestamp":1659030971000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/77\/8\/2288\/6584695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,12]]},"references-count":29,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,5,12]]},"published-print":{"date-parts":[[2022,7,28]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkac152","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,8,1]]},"published":{"date-parts":[[2022,5,12]]}}}